Bayer secures one-two treatment for liver cancer after EU approval

pharmafile | August 7, 2017 | News story | Sales and Marketing Bayer, biotech, drugs, pharma, pharmaceutical 

Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment. This means that Stivarga will be available to use after Bayer’s other therapy, Nexavar, used in first-line treatment.

The approval comes after the treatment had already been approved in the US and Japan for second-line treatment, in April and June respectively. The decision was based on the results from its RESORCE trial showed that the drug was able to improve overall survival (OS) in patients.

In the trial, OS was improved over placebo treatment by just under three months – from 7.8 to 10.6 months. This was translated as a 37% reduction in the risk of death over the duration of the trial period.

Stivarga becomes the first new drug to be approved in the most common form of liver cancer in close to a decade. The figures for survival in the area are still low in the area due to the difficulty in treating cancer once it has reached the liver.

“Until now, there was no effective second-line systemic treatment option for liver cancer patients and their treating physicians in Europe. With the EU approval of Stivarga in HCC, the outlook could significantly improve for patients with HCC, as they have now for the first time, a treatment plan with two approved therapies involving the use of Stivarga directly after Nexavar,” said Dr. Jordi Bruix, lead investigator for the RESORCE trial.

Stivarga is currently already used in the treatment of colorectal cancer and in gastrointestinal stromal tumours but has seen sales dip in these areas due to competition.

The expanded indication for treatment will then see a boost in sales that will not detract from sales of Nexavar, which continue to improve after having seen a 10% boost in sales at the beginning of this year. The current cost for treatment of Stivarga, in the US, is $14,881 for one course of treatment.

Ben Hargreaves

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content